drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody (targeted biologic)
drug_description
Humanized IgG1 monoclonal antibody binding HER2 subdomain II; blocks HER2/HER3 dimerization and mediates ADCC.
nci_thesaurus_concept_id
C38692
nci_thesaurus_preferred_term
Pertuzumab
nci_thesaurus_definition
A humanized recombinant monoclonal antibody directed against the extracellular dimerization domain of the HER-2 tyrosine kinase receptor. Binding of the antibody to the dimerization domain of the HER-2 tyrosine kinase receptor protein directly inhibits the ability of the HER-2 tyrosine kinase receptor protein (the most common pairing partner) to dimerize with other HER tyrosine kinase receptor proteins; inhibiting receptor protein dimerization prevents the activation of HER signaling pathways, resulting in tumor cell apoptosis. (NCI04)
drug_mesh_term
Pertuzumab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Humanized IgG1 monoclonal antibody targeting the HER2 extracellular dimerization domain (subdomain II); blocks HER2/HER3 dimerization, inhibiting downstream PI3K/AKT/MAPK signaling, and engages Fc-mediated ADCC to promote tumor cell killing.
drug_name
Pertuzumab
nct_id_drug_ref
NCT06441890